M&A Deal Summary

BioVie Acquires NeurMedix

On April 27, 2021, BioVie acquired life science company NeurMedix for 10M USD

Acquisition Highlights
  • This is BioVie’s 2nd transaction in the Life Science sector.
  • This is BioVie’s largest (disclosed) transaction.
  • This is BioVie’s 2nd transaction in the United States.
  • This is BioVie’s 1st transaction in California.

M&A Deal Summary
Date 2021-04-27
Target NeurMedix
Sector Life Science
Buyer(s) BioVie
Deal Type Add-on Acquisition
Deal Value 10M USD
Advisor(s) GreenbergTraurig (Legal)

Target

NeurMedix

San Diego, California, United States
NeurMedix is a clinical-stage biopharmaceutical company that engages in developing products for the treatment of neurological and neurodegenerative disorders, and certain oncological diseases. NeurMedix is based in San Diego, California.

Search 198,435 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

BioVie

Santa Monica, California, United States
Category Company
Founded 2013
Sector Life Science
Employees6
DESCRIPTION

BioVie is a development stage company focused on the discovery, development, and commercialization of novel drug therapies. BioVie was founded in 2013 and is based in Beverly, Massachusetts. BioVie was founded in 2013 and is headquartered in Santa Monica, California.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (California) 1 of 1
Country (United States) 2 of 2
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-04-18 LAT Pharma

Chicago, Illinois, United States

LAT Pharma LLC is a biotechnology company developing novel medicines to treat life-threatening complications of liver cirrhosis.

Buy -
Mergr

Product

Company

Legal